Alliance Global Partners: Maintains Verastem (VSTM.US) rating, adjusted from buy to buy rating, and adjusted target price from $34.00 to $20.00.
Assertio Holdings (ASRT.US) was first covered by Alliance Global Partners, giving it a buying rating, with a target price of $2.75.
Alliance Global Partners: Downgraded Perfusion (PRFT.US) rating from buy to neutral.
Alliance Global Partners: Upgraded Perfusion (PRFT.US) rating from neutral to buy rating.
Alliance Global Partners: Maintains TRX Gold (TRX.US) rating, adjusted from buy to buy rating, and adjusted target price from $1.50 to $1.75.
Alliance Global Partners Maintains Buy on TRX Gold, Raises Price Target to $1.75
Alliance Global Partners Upgrades OrganiGram Holdings to Buy, Announces C$4.25 Price Target
Alpine Income Prop Trust (PINE.US) was first covered by Alliance Global Partners, giving it a buying rating, with a target price of $19.00.
CTO Realty Growth (CTO.US) was first covered by Alliance Global Partners and given a buying rating, with a target price of $20.00.
Alliance Global Partners Initiates Coverage On CTO Realty Growth With Buy Rating, Announces Price Target of $20
Alliance Global Partners Maintains Buy on Atlas Lithium, Lowers Price Target to $55
Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target
Alliance Global Partners Initiates Coverage On Fortress Biotech With Buy Rating, Announces Price Target of $5
Alliance Global Partners Maintains Buy on Boxlight, Lowers Price Target to $2.5
Alliance Global Partners Upgrades Aurora Mobile to Buy, Announces $7 Price Target
Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating
Alliance Global Partners Initiates Coverage On Journey Medical With Buy Rating, Announces Price Target of $8.5
Alliance Global Partners Initiates Coverage On RenovoRx With Buy Rating, Announces Price Target of $4
Alliance Global Partners Initiates Coverage On Amplify Energy With Buy Rating, Announces Price Target of $9
Alliance Global Partners Initiates Coverage On ProSomnus With Buy Rating, Announces Price Target of $2
No Data